COVID-19-associated arrhythmia and conduction system disease

WikiDoc Resources for COVID-19-associated arrhythmia and conduction system disease
Articles
Most recent articles on COVID-19-associated arrhythmia and conduction system disease Most cited articles on COVID-19-associated arrhythmia and conduction system disease Review articles on COVID-19-associated arrhythmia and conduction system disease Articles on COVID-19-associated arrhythmia and conduction system disease in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on COVID-19-associated arrhythmia and conduction system disease Images of COVID-19-associated arrhythmia and conduction system disease Photos of COVID-19-associated arrhythmia and conduction system disease Podcasts & MP3s on COVID-19-associated arrhythmia and conduction system disease Videos on COVID-19-associated arrhythmia and conduction system disease
Evidence Based Medicine
Cochrane Collaboration on COVID-19-associated arrhythmia and conduction system disease Bandolier on COVID-19-associated arrhythmia and conduction system disease TRIP on COVID-19-associated arrhythmia and conduction system disease
Clinical Trials
Ongoing Trials on COVID-19-associated arrhythmia and conduction system disease at Clinical Trials.gov Trial results on COVID-19-associated arrhythmia and conduction system disease Clinical Trials on COVID-19-associated arrhythmia and conduction system disease at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on COVID-19-associated arrhythmia and conduction system disease NICE Guidance on COVID-19-associated arrhythmia and conduction system disease NHS PRODIGY Guidance FDA on COVID-19-associated arrhythmia and conduction system disease CDC on COVID-19-associated arrhythmia and conduction system disease
Books
Books on COVID-19-associated arrhythmia and conduction system disease
News
COVID-19-associated arrhythmia and conduction system disease in the news Be alerted to news on COVID-19-associated arrhythmia and conduction system disease News trends on COVID-19-associated arrhythmia and conduction system disease
Commentary
Blogs on COVID-19-associated arrhythmia and conduction system disease
Definitions
Definitions of COVID-19-associated arrhythmia and conduction system disease
Patient Resources / Community
Patient resources on COVID-19-associated arrhythmia and conduction system disease Discussion groups on COVID-19-associated arrhythmia and conduction system disease Patient Handouts on COVID-19-associated arrhythmia and conduction system disease Directions to Hospitals Treating COVID-19-associated arrhythmia and conduction system disease Risk calculators and risk factors for COVID-19-associated arrhythmia and conduction system disease
Healthcare Provider Resources
Symptoms of COVID-19-associated arrhythmia and conduction system disease Causes & Risk Factors for COVID-19-associated arrhythmia and conduction system disease Diagnostic studies for COVID-19-associated arrhythmia and conduction system disease Treatment of COVID-19-associated arrhythmia and conduction system disease
Continuing Medical Education (CME)
CME Programs on COVID-19-associated arrhythmia and conduction system disease
International
COVID-19-associated arrhythmia and conduction system disease en Espanol COVID-19-associated arrhythmia and conduction system disease en Francais
Business
COVID-19-associated arrhythmia and conduction system disease in the Marketplace Patents on COVID-19-associated arrhythmia and conduction system disease
Experimental / Informatics
List of terms related to COVID-19-associated arrhythmia and conduction system disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Historical Perspective

• [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
• In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
• In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• Respiratory disease is the chief target of Coronavirus disease 2019 (COVID-19).
• One-third of patients with severe disease also reported other symptoms including arrhythmia. According to a study done in Wuhan, China, 16.7% of hospitalized and 44.4% of ICU patients with COVID-19 had arrhythmias.
• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes S-spike to bind to angiotensin-converting enzyme 2 (ACE2) receptors to enter the cells.
• Type 1 and type 2 pneumocytes exhibit ACE 2 receptors in the lung. Studies report that coronary endothelial cells in the heart and intrarenal endothelial cells and renal tubular epithelial cells in the kidney exhibit ACE2. ACE2 is an inverse regulator of the renin-angiotensin system.
• The interaction between SARS-CoV2 and ACE2 can bring about changes in ACE2 pathways prompting intense injury to the lung, heart, and endothelial cells. Hypoxia and electrolyte abnormalities that are common in the acute phase of severe COVID-19 can potentiate cardiac arrhythmias.
• Binding of SARS-CoV-2 to ACE2 receptors can result into hypokalemia which causes various types of arrhythmia.
• Elevated levels of cytokines as a result of the systemic inflammatory response of the severe Coronavirus disease 2019 (COVID-19) can cause injury to multiple organs, including cardiac myocytes.
• According to the data based on studies on previous Severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) epidemic and the ongoing COVID-19 outbreak, multiple mechanisms have been suggested for cardiac damage.

Differentiating [disease name] from other Diseases

• [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop [disease name].

• [Disease name] is more commonly observed among patients aged [age range] years old.
• [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

• [Disease name] affects men and women equally.

• [Gender 1] are more commonly affected with [disease name] than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for [disease name].

• [Disease name] usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop [disease name].

Risk Factors

• Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• [Disease name] is usually asymptomatic.
• Symptoms of [disease name] may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with [disease name] usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with [disease name].

• A [positive/negative] [test name] is diagnostic of [disease name].
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
• Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with [disease name].

• [Imaging study 1] is the imaging modality of choice for [disease name].
• On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• [Disease name] may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for [disease name]; the mainstay of therapy is supportive care.

• The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action 1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for [disease name].
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
• [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].